Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

News

Strong action is needed to preserve the competitiveness of America’s life-science industries

Washington D.C. – Living standards in the United States increasingly depend on the competitiveness of industries that compete internationally, particularly those that succeed by producing new innovations.

The life-science sector, which includes pharmaceuticals, biotechnology, and medical devices, is one of those industries. It is also an American success story: Our country captures more than 40 percent of the world’s major patents in both pharmaceuticals and medical devices. But as described in a new report written for the Information Technology and Innovation Foundation, the continued health of the U.S. life-sciences sector is at risk because a growing number of foreign competitors are making determined efforts to gain global market share, often using unfair tactics.

Read more here.

HINJ President Testifies at Inaugural Assembly Science, Innovation and Technology Committee

Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ), testified February 1 at the inaugural hearing of the Assembly Science, Innovation and Technology Committee.

Dean J. Paranicas, President of HINJ, testifying Feb. 1 in Trenton

Paranicas said the panel will play a valuable role by focusing on the needs of New Jersey’s innovation economy, “which has a long legacy as a global leader spanning more than a century in chemicals, pharmaceuticals, telecommunications and food processing, all of which have their roots here.”

The state has made tremendous progress to foster innovation and research in recent years, he said, but more needs to be done. Along with offering specific recommendations, the HINJ President said: “A state’s attitude goes a long way in setting the tone.  In our case, New Jersey needs to embrace the life sciences as Texas embraces oil and gas and Michigan embraces the automobile industry.”

Paranicas commended Assembly Speaker Craig Coughlin for establishing the committee and expressed appreciation to Assemblyman Andrew Zwicker for agreeing to serve as Chairman and to the Committee members for their participation.

The full text of Paranicas’ testimony is posted on the HINJ website here.

HINJ’s ‘Value of Medical Innovation’ Portal Showcases How Life Sciences Is Saving Money — And Lives

New Brunswick, NJ, December 1, 2017 ― The HealthCare Institute of New Jersey (HINJ) continues to update its Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of research-driven medical innovation, which saves money — and saves lives.

Introduced in September 2015, HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), U.S. government sources and various medical research organizations. Continue reading

Rutgers Cancer Institute, Rutgers Health and University Hospital Unite with American Cancer Society to Fight Colorectal Cancer

New Brunswick, NJ, November 30, 2017 — Rutgers Cancer Institute of New Jersey, Rutgers Health, and University Hospital in Newark have announced their commitment to increase colorectal cancer screening across New Jersey by joining a national effort with the American Cancer Society in the fight against this disease.

Through proper screening, doctors can find and remove hidden growths (called “polyps”) in the colon before they become cancerous.

A first-time screening is recommended for men and women beginning at age 50.  One should discuss appropriate screening intervals with their health professional based on age, health history and family history of the disease.  Those with a family history of the disease may be encouraged to start a screening regimen at a younger age. Continue reading

Poll Respondents Appreciate Innovation’s Economic, Social Benefits And Call For More Protections

Washington, DC, November 30, 2017Mark Grayson, deputy vice president of public affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), posts on the association’s blog, The Catalyst, that, increasingly, economists and international organizations are recognizing innovation as one of the most important drivers of economic and social progress and stability.

In fact, a report released earlier this year from the Global Intellectual Property Center, declared a robust innovation environment as “essential to the success of any 21st century economy.”

However, Grayson says it’s not just think tanks and academics acknowledging the value of innovation — the public is as well. Continue reading

United Nations Report: Nearly 21 Million Now Receiving AIDS Drugs

Cape Town and Geneva, November 30, 2017 — Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly.

In 2000, just 685 000 people living with HIV had access to antiretroviral therapy.  By June 2017, around 20.9 million people had access to the life-saving medicines.

Such a dramatic scale-up could not have happened without the courage and determination of people living with HIV demanding and claiming their rights, backed up by steady, strong leadership and financial commitment. Continue reading

National Organizations Support Outreach Efforts for NIH’s ‘All of Us’ Research Program

Bethesda, MD, November 29, 2017 — Fourteen national community groups and health care provider associations have partnered with the All of Us Research Program, part of the National Institutes of Health, to help raise awareness about the program — an effort to engage 1 million or more volunteers across the country to build one of the largest, most diverse datasets of its kind for health research.

This inaugural group of organizations will receive a combined $1 million to help educate their communities about the benefits of participation in this landmark project to accelerate breakthroughs in precision medicine.

“We want to build long-term relationships with our participants based on transparency and trust. These organizations will help us in that effort,” said Eric Dishman, director of the All of Us Research Program at NIH. Continue reading

NJ Economic Development Administration Awards $46M to 39 Companies

Trenton, NJ, November 29, 2017 — Continuing efforts to foster the growth of the State’s burgeoning technology industry, the New Jersey Economic Development Authority (EDA) announced on November 6 that 39 companies have been approved to share over $46 million through New Jersey’s Technology Business Tax Certificate Transfer (NOL) Program.

Administered by EDA and the New Jersey Department of Treasury’s Division of Taxation, this competitive program enables qualified, unprofitable technology and biotechnology companies to sell net operating losses and/or research and development tax credits to raise cash to finance their growth and operations. Continue reading

Mayors Committee on Life Sciences Patient Courage Award Presented to Ralph Wehmann in Alpine

(L. to r.) Ralph Wehmann, Alpine Mayor Paul Tomasko and Dean Paranicas

Alpine, NJ, November 28, 2017 —The Mayors Committee on Life Sciences on November 20 presented its Patient Courage Award to Alpine resident Ralph Wehmann, in recognition of his strength in the face of adversity and commitment to helping others.

The honor was presented by Dean J. Paranicas, who serves as President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ) and a Co-Chair of We Work for Health New Jersey, during the Alpine Mayor and Council meeting.

Mr. Wehmann’s battle with myelodysplastic syndrome (MDS) began in 2012. It was not his first brush with a life-threatening illness, so it came as no surprise to those that know him that he fought back with the same determination and positive spirit he had demonstrated previously. Continue reading

Medical Innovation: FDA OKs Pill with Sensor that Digitally Tracks If Patients Have Ingested Medication

Washington, DC, November 28, 2017 — The U.S. Food and Drug Administration (FDA) on November 13 approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken.

The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

The system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Continue reading